Edgewise Therapeutics, Inc. EWTX
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- +60.78%
- 1 year
- +79.35%
5D -4.33 (-9.34%)
- Market cap
- 4.37B
- EPS (ttm)
- 8.38
- Shares out
- 109.48M
- P/E ratio
- 4.76
- Forward P/E
- -20.34
- YTD return
- +60.78%
- 1-year return
- +79.35%
- 50-day average
- 41.23
- 200-day average
- 37.27
- Enterprise value
- 2.77B
- Volume
- 1.11M
- Avg volume
- 1.53M
- Open
- 40.81
- Previous close
- 41.17
- Day's range
- 39.71 – 41.40
- 52-week range
- 19.76 – 48.78
- Beta
- 0.40
- Analysts
- Strong Buy
- Price target
- 55.42 (+38.9%)
- Earnings date
- Feb 25, 2027
Key statistics
- Price / book
- 2.67
- Free cash flow
- 6.55M
- Total cash
- 1.74B
- Total debt
- 3.38M
- Return on equity
- 92.14%
- Short % of float
- 16.29%
Fundamental scorecard
9 of 25 checks passed on EWTX’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 2 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 36.00
- Target (mean)
- 55.42
- Target (high)
- 85.00
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.42762.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.42252 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.53198 | 9.65 | +10.18 | +1,913.98% |
| Aug 6, 2026 | Jun 30, 2026 | -0.46769 | -0.53 | -0.06 | -13.32% |
| May 7, 2026 | Mar 31, 2026 | -0.50 | -0.46 | +0.04 | +8.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.43 | -0.47 | -0.04 | -9.30% |
| Nov 6, 2025 | Sep 30, 2025 | -0.40 | -0.39 | +0.01 | +2.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Sep 21, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 20, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 11, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 20, 2026 | Evercore ISI Group | main | Outperform | Outperform |
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- edgewisetx.com
News
JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $69
Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51
Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting
Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate
Your note
Sign in to keep a note on EWTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARRUTHERS ROBERT MICHAEL | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 11, 2025 | 86,162 |
| DERAKHSHAN BEHRAD | Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 31,826 |
| DONOVAN JOANNE M | Officer | Sale | Nov 15, 2026 | 8,139 |
| EDRIS BADREDDIN | Director | Conversion of Exercise of derivative security | Jan 20, 2026 | 19,820 |
| FOX JONATHAN C | Director | Stock Award(Grant) | Jun 30, 2026 | 24,833 |
| KOCH KEVIN | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 52,488 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 14.17% | 15,518,492 | 618.88M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 9.85% | 10,778,665 | 429.85M | Sep 29, 2026 |
| RA Capital Management, L.P. | 7.67% | 8,392,730 | 334.70M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 6.67% | 7,298,520 | 291.06M | Sep 29, 2026 |
| Blackrock Inc. | 6.64% | 7,274,226 | 290.10M | Sep 29, 2026 |
| Novo Holdings A/S | 4.89% | 5,350,000 | 213.36M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.65% | 2,902,230 | 115.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.69% | 1,855,091 | 73.98M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.79% | 864,638 | 34.48M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.78% | 856,214 | 34.15M | Sep 29, 2026 |
| Victory Portfolios IV-Victory Pioneer Select Mid Cap Growth Fund | 0.73% | 794,393 | 31.68M | Aug 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.72% | 783,189 | 31.23M | Aug 30, 2026 |
